Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimicotinib in chronic graft-versus-host disease
NCT06186804Phase 2Enrolling by invitation
- Sponsor
- Abbisko Therapeutics
- Start
- May 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pimicotinib in chronic graft-versus-host disease (cGVHD), sponsored by Abbisko Therapeutics. Started May 2023; status: enrolling by invitation.
02
Drugs
pimicotinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06186804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06186804.